Patents by Inventor Stuart Alexander Cook
Stuart Alexander Cook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190241637Abstract: Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition of IL-11-mediated signalling.Type: ApplicationFiled: October 12, 2018Publication date: August 8, 2019Applicants: Singapore Health Services PTE LTD, National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer, Wei Wen Lim, Benjamin Wei Ming Ng
-
Publication number: 20190002553Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 21, 2018Publication date: January 3, 2019Applicants: Singapore Health Services PTE LTD., National University of SingapoInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180371078Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 21, 2018Publication date: December 27, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180371077Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 21, 2018Publication date: December 27, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362638Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362634Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362637Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362636Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362640Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362641Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 21, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362633Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362639Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180362635Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: August 6, 2018Publication date: December 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Patent number: 10106603Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: GrantFiled: May 24, 2018Date of Patent: October 23, 2018Assignees: Singapore Health Services PTE LTD, National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180265579Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: May 24, 2018Publication date: September 20, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Patent number: 10035852Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: GrantFiled: December 16, 2016Date of Patent: July 31, 2018Assignees: Singapore Health Services PTE LTD, National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180186871Abstract: IL-11 antibodies are disclosed. Also disclosed are compositions comprising the IL-11 antibodies, and methods using the IL-11 antibodies.Type: ApplicationFiled: December 15, 2017Publication date: July 5, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20180186872Abstract: IL-11Ra antibodies are disclosed. Also disclosed are compositions comprising the IL-11Ra antibodies, and methods using the IL-11Ra antibodies.Type: ApplicationFiled: December 15, 2017Publication date: July 5, 2018Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20170174759Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: December 16, 2016Publication date: June 22, 2017Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
